What question did this study set out to answer?

To determine whether adding pimobendan to conventional therapy reduces morbidity and case fatality in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.

July 1, 2008Journal of Veterinary Internal Medicine

Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy

View Full Paper

Ask AI

Bookmark

Why the study?

Does pimobendan reduce treatment failure in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy?

Key Points

To determine whether adding pimobendan to conventional therapy reduces morbidity and case fatality in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
Prospective, randomized, double-blind, placebo-controlled trial in N=16 Doberman Pinschers with congestive heart failure secondary to dilated cardiomyopathy.
Dogs received standard baseline therapy with furosemide and benazepril hydrochloride (0.5 mg/kg PO q12h) and were randomized in pairs and by sex to receive either pimobendan (0.25 mg/kg PO q12h) or placebo.
Primary endpoint was time to treatment failure; secondary endpoints were quality-of-life indices.
Pimobendan significantly increased time to treatment failure compared to placebo (median 130.5 days vs. 14 days; P = .002; risk ratio = 0.35, 95% CI 0.13–0.71, P = .003).
The rapid rate and high frequency of treatment failure among placebo-treated dogs precluded statistical analysis of quality-of-life scores.

Structured PICO

Does pimobendan reduce treatment failure in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy?

Population

16 Doberman Pinschers in congestive heart failure (CHF) caused by dilated cardiomyopathy (DCM).

Intervention

Pimobendan (0.25 mg/kg PO q12h) added to conventional therapy (furosemide PO as required and benazepril hydrochloride 0.5 mg/kg PO q12h).

Comparator

Placebo (1 tablet PO q12h) added to conventional therapy.

Outcome

Treatment failurehard clinical

Pimobendan significantly prolongs time to treatment failure when added to conventional therapy in Doberman Pinschers with CHF caused by DCM.

Limitations

Number and rate of dogs reaching treatment failure in the placebo group precluded the analysis of QoL.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports pimobendan evaluation in canine DCM; hypothesis-generating and should not yet change practice.

Cite This Study

O'Grady et al. (2008) studied this question.

synapsesocial.com/papers/6a70c8a3fe4101aa97e04f15 https://doi.org/10.1111/j.1939-1676.2008.0116.x

Topics

Heart failure HFrEF treatment

View Full Paper

Ask AI

Bookmark

Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Topics

Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy

Key Points

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider